




































Modified Nucleosides


Cat. No. CS-0100774 Purity: 97%  CAS: 163759-49-7	Cat. No. CS-0097284 Purity: 97%  CAS: 64183-27-3	Cat. No. CS-W012725 Purity: 98%  CAS: 10212-20-1	Cat. No. CS-W012234 Purity: 98%  CAS: 78842-13-4	Cat. No. CS-0100721 Purity: 97%  CAS: 114748-67-3
Cat. No. CS-0100782 Purity: 97%  CAS: 172163-62-1	Cat. No. CS-W013768 Purity: 98.5%  CAS: 14985-44-5	Cat. No. CS-0027826 Purity: 98%  CAS: 34408-14-5	Cat. No. CS-0506463 Purity: 98%  CAS: 120595-72-4	Cat. No. CS-W012428 Purity: 98%  CAS: 10414-81-0

Phosphoramidates

Cat. No. CS-W013784 Purity: 98%  CAS: 98796-51-1	Cat. No. CS-W009564 Purity: 97%  CAS: 93183-15-4	Cat. No. CS-0159225 Purity: 95%  CAS: 150780-67-9	Cat. No. CS-B1581 Purity: 98%  CAS: 136834-22-5	Cat. No. CS-0147075 Purity: 97%  CAS: 146954-75-8
Cat. No. CS-0159224 Purity: 95+%  CAS: 110764-78-8	Cat. No. CS-0159231 Purity: 98%  CAS: 1027734-01-5	Cat. No. CS-0159238 Purity: 98%  CAS: 154110-40-4	Cat. No. CS-0149454 Purity: 98%  CAS: 109389-30-2	Cat. No. CS-0159236 Purity: 98%  CAS: 330628-04-1
Cat. No. CS-0199871 Purity: 98%  CAS: 2245842-16-2	Cat. No. CS-0159222 Purity: 98%  CAS: 161442-19-9	Cat. No. CS-0159227 Purity: 97%  CAS: 110782-31-5	Cat. No. CS-W013775 Purity: 98%  CAS: 98796-53-3	Cat. No. CS-0649968 Purity: 98%  CAS: 1190089-70-3

Nucleotides

Cat. No. CS-W009878 Purity: 97%  CAS: 63-37-6	Cat. No. CS-W011728 Purity: 98%  CAS: 4578-31-8	Cat. No. CS-W013891 Purity: 98%  CAS: 3387-36-8	Cat. No. CS-0059479 Purity: 97%  CAS: 146-91-8	Cat. No. CS-W014440 Purity: 95%  CAS: 54735-61-4
Cat. No. CS-0149518 Purity: 98%  CAS: 115899-39-3	Cat. No. CS-W013816 Purity: 98%  CAS: 36051-68-0	Cat. No. CS-0132970 Purity: 98%  CAS: 54680-12-5	Cat. No. CS-0505710 Purity: 98%  CAS: 902-04-5	Cat. No. CS-W009617 Purity: 97%  CAS: 72696-48-1



Nucleosides and Nucleotides

Protective Nucleosides

Modified Nucleosides

Phosphoramidates

Nucleotides

ChemScene LLC

Email:
sales@chemscene.com

Address:
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA


Oligonucleotides

As the third generation of revolutionary therapies, oligonucleotide drugs have seen rapid global industrial development and the rise of the domestic track. In 2026, new drugs were approved clinically and R&D platforms were launched, with frequent large-scale investments and overseas licensing in the industrial sector; the global and domestic market scales are growing rapidly with huge commercial potential, and high-purity nucleoside monomers are the core guarantee for their development.

As a key category of precision therapies, oligonucleotide drugs are experiencing rapid global development, covering ASOs, siRNAs and aptamers, and becoming pivotal in treating genetic and rare diseases. In 2026, remarkable progress has been made in clinical research, technology and industry.

Nucleoside monomers are the fundamental building blocks of oligonucleotide drugs, playing an irreplaceable core role in their synthesis and performance optimization. High-purity nucleoside monomers, including natural and modified types, are essential for automated solid-phase synthesis of ASOs, siRNAs and other oligonucleotide drugs. Their structural modifications directly determine the drugs' nuclease resistance, target affinity and in vivo half-life, reducing off-target effects and improving therapeutic efficacy. As the global oligonucleotide drug industry advances rapidly, high-quality nucleoside monomers become the key guarantee for clinical R&D progress and large-scale industrial production.

End-to-end oligonucleotide synthesis from nucleosides to phosphoramidites to oligonucleotides




Oligonucleotides Solid-Phase Synthesis Cycle Steps

Detritylation: Use TCA to remove the 5' DMT protecting group of the nucleoside, releasing free 5' OH for monitoring coupling efficiency.

Coupling: Activate nucleoside monomers under ETT catalysis; react with free 5' OH to form phosphite triester linkages, enabling nucleoside coupling.

Oxidation: Oxidize unstable phosphite triester linkages to stable phosphotriester linkages with iodine, preparing for the next cycle.

Capping: Acetylate unreacted 5' OH to terminate further reaction, reduce impurities, and improve product purity.



Protective Nucleosides

Cat. No. CS-0686480 Purity: 95% CAS: 110522-74-2	Cat. No. CS-W011841 Purity: 97% CAS: 4546-72-9	Cat. No. CS-W016727 Purity: 98% CAS: 68892-42-2	Cat. No. CS-0188300 Purity: 97% CAS: 32909-05-0	Cat. No. CS-0151331 Purity: 95% CAS: 17331-13-4
Cat. No. CS-0003164 Purity: 96% CAS: 251647-48-0	Cat. No. CS-W011418 Purity: 98% CAS: 68892-41-1	Cat. No. CS-0199873 Purity: 97% CAS: 85079-00-1	Cat. No. CS-W012441 Purity: 98% CAS: 2002-35-9	Cat. No. CS-01720188 Purity: 97% CAS: 113886-71-8
Cat. No. CS-0132079 Purity: 98% CAS: 136834-20-3	Cat. No. CS-0021845 Purity: 98% CAS: 81265-93-2	Cat. No. CS-0159293 Purity: 98% CAS: 110522-82-2	Cat. No. CS-0159309 Purity: 98% CAS: 81256-87-3	Cat. No. CS-0145610 Purity: 98% CAS: 21090-30-2
Cat. No. CS-0160913 Purity: 97% CAS: 666848-11-9	Cat. No. CS-0159258 Purity: 98% CAS: 51549-36-1	Cat. No. CS-0159308 Purity: 98% CAS: 123956-65-0	Cat. No. CS-W018965 Purity: 95% CAS: 81256-88-4	Cat. No. CS-0675482 Purity: 98% CAS: 14270-73-6

Modified Nucleosides

Cat. No. CS-W012268 Purity: 98% CAS: 2140-79-6	Cat. No. CS-W013976 Purity: 98% CAS: 2140-71-8	Cat. No. CS-0166797 Purity: 97% CAS: 55486-09-4	Cat. No. CS-0100781 Purity: 98% CAS: 168427-74-5	Cat. No. CS-0114223 Purity: 98% CAS: 473278-54-5
---	---	--	---	---